Business NewsEventsNewsPayersPhysiciansProduct NewsResearchers

MERZ REGAINS SOLE DISTRIBUTION OF ASCLERA FROM ANGIODYNAMICS

 

Merz North America Inc. has regained exclusive distribution of Asclera (polidocanol) Injection in the United States to all healthcare practitioners and phlebologists treating varicose veins.

Also effective April 8, AngioDynamics Inc. is no longer an authorized distributor of Asclera.

All HCPs will now be able to purchase Asclera directly from Merz. This includes specialties such as vascular surgery, interventional radiology, general surgery, plastic surgery, cardiology, vein clinics, and vein centers, as well as hospitals.

Jon Parrish, vice president of commercial development at Merz, said this provides all present and future customers the ability to purchase Asclera directly from Merz by calling 844-4MY-MERZ (844-469-6379).

“All accounts will benefit from dedicated support of an account specialist representative from Merz,” Parrish said. “Merz will maintain Asclera part numbers and continue to honor current product list prices.”

The Asclera part number for Asclera (polidocanol) Injection 0.5 percent remains Number 7220121 and the NDC remains 46783-121-52. Part number for Asclera (polidocanol) Injection 1 percent remains 7220221 and the NDC remains 46783-221-52.

Full prescribing information and safety information is available at Asclera.com).

In a letter to customers April 8, Parrish assured customers that their success was the primary concern of Merz.

“We appreciate the opportunity to partner with you to better serve your practice and to help you attain real clinical results that help your patients live better, feel better and look better,” Parrish said. “As always, your success is our success.”

Merz reports clinical results that 95 percent of patients treated with Asclera showed good improvement or complete treatment success as rated by physicians.

Also citing a 2010 double-blind, randomized, comparative clinical trial of polidocanol, sodium tetradecyl sulphate and isotonic saline (EASI study) by Rabe E, Schliephake D, Otto J, Breu F, Pannier F. Sclerotherapy of telangiectases and reticular veins IN Phlebology, the company also noted that 87 percent of patients were satisfied or very satisfied with their Asclera treatment at 12 weeks. VTN

Previous post

NEVER SAY DIE: WHY MOST DOCTORS WON’T BREAK BAD NEWS

Next post

VECLOSE EXTENSION STUDY: Five-year outcomes prove durability, safety, efficacy of VenaSeal Closure System

Larry Storer

Larry Storer

Larry Storer has been editor of Vein Therapy News for 10 years. He has edited computer, shelter and medical publications at Publications & Communications LP for 30 years. He was also a corporate vice president and editorial director before retiring. Larry graduated from Baylor University with a BA in journalism and an MA in communications; and from Lamar University with a MED in school administration. He taught beginning and advanced reporting, beginning and advanced editing and editorial writing at Baylor University. Larry was a reporter, and city and news editor of the Beaumont Journal, and opinion editor at the Beaumont Enterprise and Beaumont Enterprise-Journal. He was also the founding managing editor of the Yuba City (California) Daily Independent-Herald.